Albumin-Bound Paclitaxel
Showing 1 - 25 of 4,750
Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Zimberelimab
- +2 more
-
Xi'an, Shaanxi, ChinaHongxi Zhao
Sep 20, 2023
PDAC - Pancreatic Ductal Adenocarcinoma Trial (Combination of sitagliptin+ gemcitabine + nab-paclitaxel)
Not yet recruiting
- PDAC - Pancreatic Ductal Adenocarcinoma
- Combination of sitagliptin+ gemcitabine + nab-paclitaxel
- (no location specified)
Jul 9, 2023
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
Pancreatic Cancer Trial in Tianjin (surufatinib + gemcitabine + nab-paclitaxel)
Recruiting
- Pancreatic Cancer
- surufatinib + gemcitabine + nab-paclitaxel
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jun 15, 2023
Locally Advanced Pancreatic Cancer Trial in Shanghai (Tumor treating fields combined with Gemcitabine HCl and albumin binding
Not yet recruiting
- Locally Advanced Pancreatic Cancer
- Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel
- Gemcitabine hydrochloride and albumin binding paclitaxel
-
Shanghai, Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
Dec 8, 2022
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,
Recruiting
- HNSCC
- +2 more
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Aug 6, 2023
Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)
Recruiting
- Breast Cancer
- Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
-
Chengdu, Chengdu, Sichuan, China, ChinaWest China Hospital, Sichuan University
Oct 7, 2022
Early Breast Cancer Trial in Zhengzhou (monosialic gangliosides, Placebo)
Withdrawn
- Early Breast Cancer
- monosialic gangliosides
- Placebo
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Nov 19, 2022
Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)
Recruiting
- Angiosarcoma Metastatic
- Abraxane combined with liposomal doxorubicin
-
Guangzhou, Guangdong, ChinaXing Zhang
Sep 4, 2022
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory
Active, not recruiting
- Locally Advanced Breast Carcinoma
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +3 more
Jan 31, 2023
Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and
Recruiting
- Ovarian Carcinoma
- +6 more
- Albumin-bound paclitaxel and bevacizumab
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Recurrent Cervical Cancer Trial in Guangzhou (anti-PD-1+Albumin-Bound Paclitaxel)
Active, not recruiting
- Recurrent Cervical Cancer
- anti-PD-1+Albumin-Bound Paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 26, 2022
Breast Cancer Trial in Beijing (doxorubicin, epirubicin, pirarubicin)
Not yet recruiting
- Breast Cancer
- doxorubicin
- +6 more
-
Beijing, Beijing, ChinaCancer Hospital, ChineseAMS
Mar 17, 2022
Ovarian Cancer Trial (albumin-bound paclitaxel, paclitaxel)
Not yet recruiting
- Ovarian Cancer
- albumin-bound paclitaxel
- paclitaxel
- (no location specified)
Mar 31, 2022
Advanced Gastric Adenocarcinoma Trial in Ho-nan (Camrelizumab, Albumin-bound paclitaxel, S-1)
Recruiting
- Advanced Gastric Adenocarcinoma
- Camrelizumab, Albumin-bound paclitaxel, S-1
-
Ho-nan, Henan, ChinaHenan Tumor Hospital
Apr 14, 2022
Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)
Not yet recruiting
- Second Line Treatment of Gastric Cancer
- Camrelizumab
- +2 more
- (no location specified)
Dec 20, 2022
Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Oral Cancer
- Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
-
Guangzhou, Guangdong, ChinaSun yat-sun memorial hospital
Jul 10, 2023
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 Trial (drug, procedure,
Not yet recruiting
- Advanced Lung Non-Small Cell Carcinoma
- +3 more
- Carboplatin
- +9 more
- (no location specified)
Oct 21, 2023
Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)
Not yet recruiting
- Breast Cancer
- Inetetamab
- +2 more
-
Beijing, ChinaCancer Hospital Chinese Academy Of Medical Sciences
Mar 14, 2022
NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)
Recruiting
- Non-small Cell Lung Cancer
- Hypofractionated radiotherapy
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen university cancer center
Nov 14, 2023
Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))
Not yet recruiting
- Gastric Adenocarcinoma
- cadonilimab combined +paclitaxel (albumin-bound)
- (no location specified)
Nov 1, 2023
Triple-negative Breast Cancer Trial in Bengbu (Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab)
Recruiting
- Triple-negative Breast Cancer
- Albumin-Bound Paclitaxel
- +2 more
-
Bengbu, Anhui, ChinaDepartment of Medical Oncology, First Affiliated Hospital of Ben
Mar 15, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Withdrawn
- Anatomic Stage III Breast Cancer AJCC v8
- +11 more
- Atezolizumab
- +2 more
- (no location specified)
Jan 5, 2023